GH Research (GHRS) announced the commencement of an underwritten public offering of $150M of ordinary shares. All of the ordinary shares are to be offered by GH Research. Cantor, Stifel and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity and Citizens JMP are acting as co-lead managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research’s GH001 Shows Promising Results in TRD Phase 2b Trial
- GH Research announces primary endpoint met in Phase 2b trial of GH001
- GH Research to Update on Promising TRD Treatment Trial
- GH Research Achieves Key Milestones in Depression Trials and Prepares FDA Response
- GH Research sees top-line data from Phase 2b trial in TRD in Q1